Crescent Biopharma, Inc. (CBIO) stock
CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 10/30
$14.37−0.39 (-2.61%)
Close on Nov 12, 2026Market cap $533.76MP/E –Yield –
Crescent Biopharma profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Crescent Biopharma's profit margin for the twelve months ending Sep 30, 2026 was -727.6%. For fiscal 2025 it was -1419.6%, against -368994.2% the year before. The highest annual figure on record is 24.0% in fiscal 2012.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1419.6% | +367574.6 |
| FY2023 | Dec 31, 2023 | -368994.2% | −306742.5 |
| FY2022 | Dec 31, 2022 | -62251.7% | −56782.8 |
| FY2021 | Dec 31, 2021 | -5469.0% | −4966.9 |
| FY2020 | Dec 31, 2020 | -502.1% | +171443.0 |
| FY2016 | Dec 31, 2016 | -171945.1% | −171881.4 |
| FY2015 | Dec 31, 2015 | -63.6% | +10.4 |
| FY2014 | Dec 31, 2014 | -74.0% | +191.6 |
| FY2013 | Dec 31, 2013 | -265.6% | −289.6 |
| FY2012 | Dec 31, 2012 | 24.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -1210.3% | +97636.7 |
| Q1 FY2026 | Mar 31, 2026 | -2240.9% | +17782.6 |
| Q4 FY2025 | Dec 31, 2025 | -214.9% | +10140109.8 |
| Q2 FY2022 | Jun 30, 2022 | -17690.1% | −16337.7 |
| Q4 FY2021 | Dec 31, 2021 | -98847.1% | −89295.6 |
| Q3 FY2021 | Sep 30, 2021 | -20023.5% | −18651.2 |
| Q2 FY2021 | Jun 30, 2021 | -10140324.6% | −10140239.5 |
| Q1 FY2021 | Mar 31, 2021 | -1352.4% | – |
| Q4 FY2020 | Dec 31, 2020 | -9551.5% | – |
| Q3 FY2020 | Sep 30, 2020 | -1372.3% | – |
| Q1 FY2020 | Mar 31, 2020 | -85.1% | – |
See a number that looks wrong?